A novel treatment for fibromyalgia improves clinical outcomes in a community-based study.

Objectives: Immunoreactant load was assessed by using lymphocyte response assay [LRA] with cell response/blastogenic mixed cell culture to determine if substitution of reactive items would be associated with remission of symptoms in subjects with fibromyalgia syndrome [FMS]. Methods: Fibromyalgia su...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Musculoskeletal Pain Vol. 6; no. 2; pp. 133 - 150
Autores principales: Deuster PA, Jaffe RM
Formato: research tables/charts Journal Article
Publicado: Taylor & Francis Ltd 1998
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Objectives: Immunoreactant load was assessed by using lymphocyte response assay [LRA] with cell response/blastogenic mixed cell culture to determine if substitution of reactive items would be associated with remission of symptoms in subjects with fibromyalgia syndrome [FMS]. Methods: Fibromyalgia subjects [N 51] were assigned to a control [C: N = I I] or treatment [T: N 40] group; C maintained usual life-styles and T, after LRA testing, underwent a program of substitution and nutritional repletion with metabolic intermediates. All subjects participated in biweekly support groups and completed questionnaires [0 months, three months, and six months] to document changes. Results: After six months T experienced 50% less pain, 70% less depression, 50% more energy, and 30% less stiffness, whereas C reported an increase in pain and depression, and comparable levels of stiffness and energy as compared to pre-program levels. Conclusions: These data suggest that reducing the inununoreactant load in FMS, while stimulating repair, may help re-establish homeostasis and neuroimmune hormonal control.